About Provatas Pharmaceuticals Private Limited
Data last updated:
Provatas Pharmaceuticals Private Limited is a private limited company based in Delhi, India. It was incorporated on 04 May 2023.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U47721DL2023PTC413605.
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Ruby Singh Kahar and Geeta Prasad Kahar.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at N – 41 D – 1977 First Floor, Block – D Suraj Park, Delhi, India – 110042.
As per the financials filed for FY 2025, the company reported a revenue of ₹50.2 Lakh, a growth of 35% compared to the previous year. For the same year it recorded a net profit of ₹59,394 (net margin 1.2%) and EBITDA of ₹80,262 (EBITDA margin 1.6%).
Court records list 1 case involving the company, including 1 filed against it; 1 case is pending.
For more details, the company can be reached via its website novotaspharma.com.
Company details
Contact details
Provatas Pharmaceuticals Private Limited's registered office is in Delhi, Delhi.
- Registered AddressN – 41 D – 1977 First Floor, Block – D Suraj Park, Delhi, India – 110042
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Provatas Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Provatas Pharmaceuticals Private Limited, buy the company report.
Financials of Provatas Pharmaceuticals Private Limited
FY 2025 filings availableProvatas Pharmaceuticals Private Limited reported revenue of ₹50.2 Lakh (up 35% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue rose 35% in the latest year. EBITDA fell 36% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Profit and Loss Statement | ||
| Revenue from Operations | ||
| Other Income | ||
| Total Revenue | ||
| Cost of Materials Consumed | ||
| Employee Benefit Expense | ||
| Finance Costs | ||
| Depreciation and Amortisation | ||
| Other Expenses | ||
| Total Expenses | ||
| EBITDA | ₹80,262 | |
| Profit Before Tax | ||
| Tax Expense | ||
| Net Profit (PAT) | ₹59,394 | |
| Balance Sheet | ||
| Share Capital | ||
| Reserves and Surplus | ||
| Net Worth (Total Equity) | ||
| Long-term Borrowings | ||
| Short-term Borrowings | ||
| Trade Payables | ||
| Total Liabilities | ||
| Fixed Assets | ||
| Investments | ||
| Inventories | ||
| Trade Receivables | ||
| Cash and Bank Balance | ||
| Total Assets | ||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Profitability | ||
| EBITDA Margin | 1.6% | |
| Net Profit Margin | 1.2% | |
| Return on Equity (ROE) | ||
| Return on Capital Employed (ROCE) | ||
| Return on Assets (ROA) | ||
| Liquidity and Debt | ||
| Current Ratio | ||
| Quick Ratio | ||
| Debt-to-Equity Ratio | ||
| Interest Coverage Ratio | ||
| Efficiency and Growth | ||
| Asset Turnover | ||
| Receivable Days | ||
| Payable Days | ||
| Inventory Days | ||
| Revenue Growth | ||
| Net Profit Growth | ||
To see the full financial statements and ratios of Provatas Pharmaceuticals Private Limited, buy the company report.
Board of directors of Provatas Pharmaceuticals Private Limited
Provatas Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ruby Singh Kahar | Director | 04 May 2023 | 3 Years 5 Months | Current |
| Geeta Prasad Kahar | Director | 04 May 2023 | 3 Years 5 Months | Current |
Peer comparison
Provatas Pharmaceuticals Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Afcus Pharmaceuticals (OPC) Private Limited | ₹50.74 Lakh (FY 2023) | 1003.0% | Chandigarh, India | |||
| Lucan Pharmaceuticals Private Limited | ₹50.57 Lakh (FY 2023) | 114.0% | Delhi, India | |||
| Azott Pharmaceuticals Private Limited | ₹50.53 Lakh (FY 2021) | -30.0% | Saraikela, Jharkhand, India | |||
| Provatas Pharmaceuticals Private Limitedthis company | ₹50.2 Lakh (FY 2025) | ₹59,394 | 1.2% | 35.0% | Delhi, India | |
| Lorica Pharmaceuticals Limited | ₹50.09 Lakh (FY 2025) | -13.0% | Badaun, Uttar Pradesh, India |
To see the full peer comparison of Provatas Pharmaceuticals Private Limited, buy the company report.
Legal cases
Provatas Pharmaceuticals Private Limited has 1 court case on record: 1 filed against it. All case is pending.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 1 | 1 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Commercial suit | Filed against the company by Novartis Ag | Pending |
To see the full case history of Provatas Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Provatas Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Provatas Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Provatas Pharmaceuticals Private Limited has 2 board changes on record since 2023: 2 appointments. The latest: Geeta Prasad Kahar was appointed as Director on 04 May 2023.
Frequently asked questions
Provatas Pharmaceuticals is an active private limited company based in Delhi, India. It was incorporated on 04 May 2023 (3+ years old) and is registered under CIN U47721DL2023PTC413605.
Provatas Pharmaceuticals has 2 current directors:
- Ruby Singh Kahar - Director
- Geeta Prasad Kahar - Director
The latest financial statements of Provatas Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2024 are in the company report.
The CIN (Corporate Identification Number) of Provatas Pharmaceuticals is U47721DL2023PTC413605. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Provatas Pharmaceuticals has 1 court case on record: 1 filed against it. 1 is pending.
Provatas Pharmaceuticals was incorporated on 04 May 2023, making it 3+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Provatas Pharmaceuticals by revenue are Afcus Pharmaceuticals (OPC) Private Limited, Lucan Pharmaceuticals Private Limited, Azott Pharmaceuticals Private Limited, Lorica Pharmaceuticals Limited, all in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading).
Geeta Prasad Kahar was appointed as Director on 04 May 2023. Ruby Singh Kahar was appointed as Director on 04 May 2023.
Provatas Pharmaceuticals can be reached through the website novotaspharma.com. Its registered office is in Delhi, India.
The registered office of Provatas Pharmaceuticals is at N – 41 D – 1977 First Floor, Block – D Suraj Park, Delhi, India – 110042.
Provatas Pharmaceuticals is registered under the jurisdiction of the Registrar of Companies (ROC), Delhi.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
